8 drug(s) with this reaction
6,595 total reports
Myocardial Infarction has been reported as an adverse reaction across 8 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 6,595 adverse event reports mention myocardial infarction in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with myocardial infarction, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have myocardial infarction listed in their FDA adverse event reports, sorted by report count:
In addition to myocardial infarction, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
8 drug(s) manufactured by Abbvie Inc have myocardial infarction listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, FENOFIBRATE, RISANKIZUMAB-RZAA, PARICALCITOL, UPADACITINIB, and others.
There are a combined 6,595 reports of myocardial infarction across 8 Abbvie Inc drug(s) in the FDA adverse event database.